What is neurodegenerative disease?

- Neurodegenerative disease indicates a range of conditions which primarily affect the neurons.

- **Neurons** are the building blocks of the nervous system and normally **don’t reproduce or replace themselves**.

- Neurodegenerative diseases are characterized by a progressive degeneration and/or death of neurons. This causes problems with movement (called ataxias), or mental functioning (called dementias).
Common features of neurodegeneration

- Genetic factors/age
- Environmental factors
- Mitochondrial dysfunction
- Oxidative stress
- Altered protein modification
- Protein misfolding
- Protein aggregation
- Neuronal death

Aging and neurodegeneration

- Aging is the major risk factor for the majority of neurodegenerative diseases
- Dementia is a worldwide public health issue, currently affecting 35 million people, with numbers expected to reach 115 million by 2050
- Prevalence of Parkinson's disease is roughly estimated to be 0.3% of the general population and 1% in those aged more than 60 years

Corbett A. et al Front Biosci. 2011; 7:184-188.
Alzheimer's disease

Is a progressive neurodegenerative disorder characterized by deposition of

- amyloid plaques
- neurofibrillary tangles,
- microglial and astroglial activation,

finally, leading to neuronal dysfunction and death.
Alzheimer’s disease

Pharmacological treatments

• Current treatments primarily focus on enhancement of cholinergic transmission.

• These treatments are only symptomatic, and no disease modifying drug is available for AD patients

• With failure of so many anti-amyloid trials, new targets are emerging such as inflammation, glucose metabolism, oxidant and carbonyl stress
Parkinson’s disease

- Parkinson’s disease (PD) is a movement disorder currently affecting around 5–6 million.
- In 2030, about 10 million or more are expected to be afflicted with PD.
- The disease is characterized by motoric deficits including resting tremor, bradykinesia (slowness in movements), postural instability and rigidity.

Depletion of striatal dopamine

Dopamine levels in a normal and a Parkinson’s affected neuron.
PD and oxidative stress

- Dopamine is inactivated by the monoamine oxidase enzyme (MAO), a reaction that yields significant amounts of hydrogen peroxide that must be continuously detoxified by intracellular antioxidants.
- Oxidative and nitrative stress occurring in substantia nigra is prominent features of this disease.
- The source of nitrogen species is related to alterations in iNOS activity. The origin of oxygen radicals is increased iron levels, alterations in antioxidant mechanisms, and mitochondrial dysfunction.

Current therapy

- At present, therapeutic strategies for the PD patient remain largely symptomatic.
- Existing pharmacological treatments come with undesirable side effects.
- Pharmacological replacement of dopamine with L-Dopa remains the gold standard for PD treatment.
Nutraceuticals

Bioavailability of nutraceuticals

- The bioavailability of nutraceuticals is largely diversified from one compound to another, due to their chemical structure. Their absorption rate, metabolism, and biological activities are affected by their composition, but also depend on the direct interaction with other dietary components, such as proteins, carbohydrates, fiber, fat and alcohol.

- In order to reach the brain, orally ingested nutraceuticals must cross two barriers, i.e. the enterocytes in the intestine and the blood–brain barrier.
The blood brain barrier

It is a membrane that prevents the uncontrolled leakage of substances from the blood into the brain.

It is a complex, dynamic, adaptable interface that controls the exchange of substances between the CNS and the blood.

- This complexity in barrier function explains much of the difficulty in developing drugs that can cross the BBB, but on the other hand it offers unique and diverse opportunities for drug development.

Curcumin

Curcumin, a diarylheptanoid polyphenol isolated from the rhizomes of Curcuma longa L., is a food spice used extensively in the Indian cuisine and Ayurvedic medicine.

Curcumin has been reported to have multiple pharmacological activities and to be effective against a wide variety of diseases due to its anti-carcinogenic, hepatoprotective, thrombosuppressive, cardioprotective, anti-arthritic, anti-infectious and neuroprotective properties.
Curcumin

- The antioxidant potential of curcumin derives from its capacity to scavenge free radicals due to its unique structure that can donate H-atoms or transfer electrons from two phenolic sites.
- As this phenolic compound is more soluble in lipophilic conditions, it performs the ROS scavenging activity most effectively within the polar cytoplasm.
- Curcumin could bind to the redox-active metals iron and copper.

Curcumin bioavailability

- Limitations for the use of curcumin in nutraceutical interventions is its **limited bioavailability** which is mainly due to:
  - poor aqueous solubility,
  - poor membrane permeability,
  - degradation and rapid metabolism (biotransformation of curcumin to curcumin O-glucuronide and curcumin O-sulfate, which are catalyzed by UDP-glucuronyltransferase and sulfotransferases in enterohepatic organ, contribute to major absorption barrier.)
How to increase curcumin bioavailability

• Physically redesigned curcumin preparations using nanoparticles, liposomes or inclusion complexes have been developed.

• Piperin has been added to curcumin preparation, piperin reduces the expression of hepatic UDP-glucuronyltransferase and sulfotransferases.

• A recent paper demonstrated that pre-treating with piperin prior to curcumin administration rather than increasing dosage of piperin is much more effective.

• Duration of piperin pre-treatment should be within 0.5 to 6 hours.

Zeng et al., Biopharm Drug Dispos. 2016 Nov 23

Curcumin effects against AD

• Curcumin decreases Aβ levels through inhibition of Aβ oligomer formation, along with decreasing oxidative stress and inflammation in mice (Fang et al., Bioorg. Med. Chem. Lett. 2014; 24:40-43).

• Curcumin nutraceutical intervention attenuated oxidative injury, microgliosis, spatial memory deficits, postsynaptic loss, and Aβ deposits in a model of AD in rats. (Frautschy et al. Neurobiology of aging. 2001;22:993–1005)
### Curcumin effects against PD

- In a mice model of PD, three weeks of curcumin treatment significantly improved behavioral alterations, oxidative damage and mitochondrial enzyme complex activities (Khatri and Juvekar Pharmacol Biochem Behav. 2016;150-151:39-47)

- Curcumin protected against 6-OHDA-induced neural impairments in rats, improving memory abilities, elevating levels of SOD and GSH-Px, and reducing concentration of malonaldehyde (MDA). In addition, dopamine levels were increased in the SN and nerve growth factor expressions was up-regulated. (Song et al., Pathol Res Pract 2016;212:247-51)

### Apigenin

- Apigenin is a flavonoid abundant in the flowers of the chamomile plant and also found in other sources such as celery, parsley, peppermint.

- Apigenin crosses the BBB.

- The half-life of apigenin in plasma was calculated to be 12 h in healthy humans.
Apigenin neuroprotective activity

• Apigenin has shown protection against Aβ induced toxicity in rat cerebral microvascular endothelial cells (Zhao et al., Mol. Cancer 2011;10:104).

• Apigenin has shown potent anti-oxidant and antiapoptotic properties, by protecting rat neuronal cells subjected to oxygen and glucose deprivation/reperfusion injury (Guo et al., Neurochem. Res. 2014;39: 2197-2210).

Apigenin animal studies

• Transgenic AD mice fed with apigenin (40 mg/kg) for 3 months have shown improvements in memory and learning deficits, and a reduction of fibrillar amyloid deposits (Zhao et al., Molecules 2013;18: 9949-9965)

• Cognitive enhancing effects have also been reported for apigenin in young male rats, showing apigenin improved memory in the passive avoidance task (Popovic et al., J. Psychopharmacol. 2014 28, 498-501)
Epigallocatechin-3-gallate from tea

Unfermented teas are derived from the steamed and dried leaves of the Camellia sinensis plant. Polyphenols from green tea have been shown to be powerful hydrogen-donating antioxidants, free radical scavengers of ROS and RNS in vitro.

Of the four major tea catechins in fresh tea leaves, epigallocatechin-3-gallate is the major constituent (~60%), followed by epigallocatechin, epicatechin and epicatechin-3-gallate (ECG).

Bioavailability

- Oral administration of EGCG at a dose of 100 mg/kg led to a Cmax of 1.52 ± 0.1 mM.
- EGCG concentrations in the brain were much lower, as a dose of 50 mg/kg only leads to tissue concentrations of approximately 5 ng EGCG/g tissue.
- After absorption, EGCG is modified by sulfation, glucuronidation, and methylation before hepatic metabolism.
- Serum half-life in mice and humans was calculated to be around 4-5 h
In vivo effect of EGCG

• AD mice treated with 20 mg/kg EGCG via intra-peritoneal injections for 60 days have shown decreased Aβ levels, via promotion of the α-secretase pathway (Rezai-Zadeh et al., J. Neurosci. 2005; 25, 8807-8814).

• Oral administration of the EGCG (50 mg/kg daily), has shown improved behavioral manifestations and cognitive impairments in AD mice (Walker et al., J. Alzheimer’s Dis. 2015; 44: 561-572).

• EGCG has also been reported to prevent neuronal cell death caused by Aβ in AD mice (Levites et al., FASEB J. 2003;17: 952-954).

Docosahexaenoic acid

• Docosahexaenoic acid is an essential omega-3 (n-3) polyunsaturated fatty acid (PUFA) that is found abundantly in marine fish.
Docosahexaenoic acid

- DHA is known to be the most important n-3 PUFA in the brain, accounting for roughly 15% of total fatty acids in grey matter, where it is enriched at synapses
- Epidemiological data indicate that a low dietary intake of n-3 PUFA is a risk factor for AD
- People who ingest higher levels of DHA are less likely to develop cognition defects and AD

DHA bioavailability

- As free acids, the fish oil fatty acids are well absorbed (>95%).
- As triacylglycerols, eicosapentaenoic acid and docosahexaenoic acid were absorbed only 68% and 57%
- DHA has a half-life of 2.5 years
- Omega-3-fatty acids can easily penetrate the BBB
- Ideal daily dose would be between 180 and 2000 mg
Cellular studies on DHA

• DHA has **anti-inflammatory effects**. It downregulates the production of proinflammatory cytokines such as IL1β, IL6 and TNF-α, and inhibit NF-kB transcriptional activity *(Mullen et al., J. Nutr. Biochem 2010; 21: 444-450)*.

• DHA provided cortical neurons in vitro a higher level of resistance to the cytotoxic effects induced by soluble Aβ oligomers *(Florent et al., J. Neurochem. 2006; 96: 385-395)*.


Human studies on DHA

• 174 subjects with mild to moderate AD were fed with n-3 or a placebo for 6 months. In the n-3 treated group a significant decrease in Mini-Mental State Examination (MMSE) decline rate has been observed when compared to the placebo group *(Freund-Levi et al., Archives Neurol. 2006; 63: 1402-1408)*.

• A study on 23 patients with mild cognitive impairment for 24 weeks using n-3 fatty acid (1.8 g/day) and placebo (olive oil) exhibited improvement in Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) compared to the placebo group *(Chiu et al., Prog. Neuro Psychopharmacol. Biol. Psychiatry 2008; 32: 1538-1544)*.
Lipoic acid

α-lipoic acid (LA) is chemically synthesized, but can be considered a natural compound as it is a naturally occurring precursor of an essential cofactor for mitochondrial enzymes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase.

LA bioavailability

- LA is a low molecular weight compound which easily penetrates the BBB.
- After crossing the BBB, LA is absorbed into cells and tissues, and it is then reduced to dihydrolipoate acting as a potent antioxidant.
- LA has a limited bioavailability (29.1 ± 10.3%) due to high first-pass metabolism.
- In humans, plasma maximum concentration (Cmax) values of 1.15 mg/mL mg have been observed for LA at a dose of 1000 mg.
Lipoic Acid and neurodegeneration

- Lipoic acid increases acetylcholine production by activation of choline acetyltransferase and increases glucose uptake
- Lipoic acid chelates redox-active transition metals, inhibiting the formation of hydroxyl radicals and ROS, increasing the levels of reduced glutathione.
- Lipoic acid can scavenge lipid peroxidation products

In vitro studies have shown that lipoic acid protects cultured hippocampal neurons from Aβ induced neurotoxicity (Zhang and Frei, FASEB J. 2001; 15: 2423-2432).

- Lipoic acid inhibits the formation of Aβ fibrils (Ono et al., Biochem. Biophysical Res. 2006; 341:1046-1052).
- Lipoic acid can also activate the Nrf2-ARE pathway and act as a glutathione (GSH)-boosting drug, increasing GSH levels in cultured astroglia by up to 1.4 fold (Steele et al., Redox Biol. 2013; 1:441-445).
Resveratrol

• Resveratrol (3, 5, 4’ etrihydroxystilbene) is a polyphenolic phytoalexin, produced in response to damage in grapevines and legumes, such as peanuts and tea.

Resveratrol

• Resveratrol exists in two geometric isomers. Cis-resveratrol is less common and very unstable, while trans-resveratrol is biologically more active than cis-isomer.

• Resveratrol demonstrates an unusually strong ability to remove free radicals thanks to the presence of three groups - OH in positions 3, 4 and 5, aromatic rings and a double bond in the molecule.

• Removing hydroxyl groups, or replacing them with -OCH3 groups, results in a loss of the antioxidant properties of the compound.
Bioavailability

- Resveratrol is poorly bioavailable to the human body.
- Enhanced absorption with methylated analogs (pterostilbene) and piperine supplements
- A dose of 25 mg leads to a plasma concentration of the free form ranged from 1 to 5 ng/mL
- Neuroprotective effects in the CNS suggest that it crosses the BBB

In vivo AD studies on resveratrol

- Resveratrol in rats reduced Aβ-induced neuronal loss and memory impairment through a reduction of iNOS expression and lipid peroxidation and an increase in the expression of heme oxygenase-1 (Huang et al., PLoS One 2011; 6: e29102).
- Dietary ingestion (300 mg/kg/day) of resveratrol to AD mice showed a large reduction of plaque formation in the medial cortex, striatum and hypothalamus (Karuppagounder et al., Neurochem. Int. 2009; 54: 111-118).
- Very few clinical studies on resveratrol have been reported.
PD studies on resveratrol

• RV exerts neuroprotective effects on dopaminergic neurons probably related to antioxidant properties of the drug (Alvira et al., Neuroscience, 2007; 147:746–756)

• RV inducing activation and expression of SIRT1 protects against pathological α-synuclein aggregation. SIRT1 can deacetylate and activate heat shock factor 1 (HSF1), which affects transcription of molecular chaperons including heat shock proteins 70 (hsp70). Hsp70 regulate homeostasis of cellular proteins decreasing the formation of abnormal protein aggregates (Westerheide et al., Science 2009; 323:1063–1066)

Sulforaphane

[Diagram showing the chemical structure and reactions of Sulforaphane]
Bioavailability of sulforaphane

- Absorption of sulforaphane depends on plant myrosinase residual activity at gut level and on the gut microbiota thioglucosidase activity.
- Sulforaphane is a lipophilic compound characterized by low molecular weight, so it can diffuse through the plasma membrane into the enterocytes.
- Once into the cell, sulforaphane is quickly conjugated to glutathione by the cytosolic enzyme glutathione-S-transferase, driving its passive absorption into the cell.

Sulforaphane in AD

- In mice, a 6 days SF treatment ameliorated cognitive dysfunction induced by Aβ exposure. In particular, SF improved spatial working memory and contextual memory (Kim et al., Amyloid 2013; 20: 7-12)
- One hypothesized mechanism by which SF could counteract Aβ peptide-induced toxicity in the brain is its direct reaction with Aβ peptides. SF binds covalently and specifically at position 16 and 28 to the free NH₂ group of N-terminal aspartic acid and the ε-amino group of lysine and reduces the inclination of Aβ to aggregate (Yasuhara et al., Brain Res 2007;1133: 49-52).
**Sulforaphane in AD**

In an AD mice model, SF significantly ameliorated the cholinergic system reactivity, increasing acetylcholine level decreasing acetylcholinesterase activity, and increasing choline acetyltransferase expression in the hippocampus and frontal cortex of mice (Lee et al., Pharmacol Res 2014; 85: 23-32).

**Sulforaphane in PD**

- SF significantly counteracted nigrostriatal neurodegeneration in mice thanks to its ability to enhance the endogenous antioxidant defense system and to counteract neuroinflammation.
- In particular, **SF activated the Nrf2** mediated pathway inducing the over-expression of HO1 and NQO1 and reduced astrogliosis, microglia activation and the release of two proinflammatory cytokines such as IL-6 and TNF-α (Kazwa et al., Antioxidants & redox signaling 2011;14: 2347-2360).
Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line

Andrea Tarozzi,* Fabiana Morroni,* Adriana Merlicco,* Silvana Hrelia,† Cristina Angeloni,* and Patrizia Hrelia*†

*Department of Pharmacology, Alma Mater Studiorum, University of Bologna, Bologna, Italy
†Department of Biochemistry "G. Moruzzi", Alma Mater Studiorum, University of Bologna, Bologna, Italy

Abstract
The total GSH depletion observed in the substantia nigra (SN) appears to be responsible for subsequent oxidative stress (OS), mitochondrial dysfunction, and dopaminergic cell loss in patients with Parkinson's disease. A strategy to prevent the OS of dopaminergic cells in the SN may be the use of chemopreventive agents as inducers of endogenous GSH antioxidants and phase 2 enzymes. In this study, we demonstrated that treatment of the dopaminergic-like neuroblastoma SH-SYSY cell line with sulforaphane (SF), a cruciferous vegetable inducer, resulted in significant increases of total GSH levels, NADPH:quinone oxidoreductase-1, GSH transferase and -reductase, but not GSH peroxidase, catalase and superoxide dismutase activities. Further, the elevations of GSH levels, GSH transferase and NADPH:quinone oxidoreductase-1 activities were correlated to an increase of the resistance of SH-SYSY cells to toxicity induced by H2O2 or 6-hydroxydopamine (6-OHDA). The treatment of SH-SYSY cells with SF was also shown to prevent various apoptotic events (mitochondrial depolarization, caspase 9 and 3 activation and DNA fragmentation) and neurosis elicited by 6-OHDA. Further, the impairment of antioxidant capacity and reactive oxygen species formation at intracellular level after exposure to 6-OHDA was effectively counteracted by pre-treatment with SF. Last, both the chemopreventive and antioxidant effects of SF were abolished by the addition of buthionine sulfone-sulfoximine, supporting the main role of GSH in the neuroprotective effects displayed by SF. These findings show that SF may play a role in preventing Parkinson's disease.

Keywords: antioxidant activity, dopaminergic cells, glutathione, neuronal death, oxidative stress, sulforaphane.

Sulfuraphane protects cortical neurons against 5-S-cysteynil-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes

David Vauzour1, Maria Buonfiglio2, Giulia Corona1, Joselita Chirafisi1, Katerina Vafeiadou1, Cristina Angeloni2, Silvana Hrelia2, Patrizia Hrelia2, and Jeremy P. E. Spencer1

1Molecular Nutrition Group, School of Chemistry, Food and Pharmacy, The University of Reading, Whiteknights, Reading, UK
2Department of Biochemistry "G. Moruzzi", University of Bologna, Bologna, Italy

The degeneration of dopaminergic neurons in the substantia nigra has been linked to the formation of endogenous neurotoxins 5-S-cysteynil-dopamine. Sulfuraphane (SFN), an isothiocyanate derived from the corresponding precursor glucoraphanate found in cruciferous vegetables has been observed to exert a range of biological activities in various cell populations. In this study, we show that SFN protects primary cortical neurons against 5-S-cysteynil-dopamine induced neuronal injury. Pre-treatment of cortical neurons with SFN (0.1-1 μM) resulted in protection against 5-S-cysteynil-dopamine-induced neurotoxicity, which peaked at 100μM. This protection was observed to be mediated by the ability of SFN to modulate the extracellular signal-regulated kinase 1 and 2 and the activation of Kcch-like ECH associated protein 1 (NF-E2-related factor-2) leading to the increased expression and activity of glutathione S-transferase (M1, M3 and M14), glutathione reductase, dihydrodiols reductase and NADPH:PH oxidoreductase-1. These data suggest that SFN stimulates the NF-E2-related factor-2 pathway of antioxidant gene expression in neurons and may protect against neuronal injury relevant to the etiology of Parkinson's disease.
Loss of proteostasis and neurodegeneration

• There is a strict association between loss of proteostasis in neurons and neurodegeneration.

• The impairment of the protein degradation system leads to an abnormal accumulation of toxic protein oligomers, which are considered the starting material for the development of neurodegenerative proteinopathy.

• The spectrum of CNS linked to proteinopathies is particularly broad and includes AD, PD, Lewy body dementia, Pick disease, frontotemporal dementia, Huntington’s disease (HD), ALS and many others.

Degradation of unwanted proteins

• Unwanted proteins are safely eliminated via two major mechanisms:
  – autophagic degradation in the lysosome
  – by targeted breakdown in the proteasome.

• Even if autophagy seems to be a less selective process compared to the proteasome, in recent years, the role of autophagy impairment in neurodegenerative disease has been widely demonstrated.
Autophagyc degradation

Autophagic pathway involves the de novo synthesis of vesicles called autophagosomes, which can embed organelles, protein aggregates, and invading pathogens.

The autophagosomes fuse with endosomal compartments to form amphisomes before fusing with the lysosome, where their contents are degraded and the resulting metabolites are recycled back to the cytoplasm.

Proteasomal degradation

- Proteasomal degradation in neurons is under the control of the peptide ubiquitin. Ubiquitin covalently binds to the target proteins in a process called conjugation, sealing the fate of proteins that are digested by the proteasome.

- The amino acids obtained by protein degradation are then reused by the cell.
Sulforaphane and protein degradation

- **SF increases the expression** of the catalytic core subunits of the proteasome, leading to enhanced proteasome activity.
- **SF induces autophagy** via extracellular signal-regulated kinase (ERK) activation, independent of Nrf2 activity in neuronal cells (Jo et al., FEBS Lett 2014; 588: 3081-3088).
- In vivo data obtained in mice, in the brain, SF is able to enhance autophagy increasing both microtubule-associated protein 1 light chain 3 (LC3)-I and LC3-II levels (Liu et al., Neurochem 2014; 129: 539-547).

Summarizing

• Nutraceuticals show different activities against neurodegeneration
• Despite encouraging animal data, the percentage of positive human trials in AD and PD is surprisingly low
• The effect of treatment appears more effective when initiated early in the disease
• Careful prospective studies with these molecules in patients with neurodegeneration may be conducted for assessing the therapeutic benefits.